Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New

被引:21
|
作者
Mackenzie, Samuel J. [1 ,2 ]
Nicolau, Stefan [1 ]
Connolly, Anne M. [1 ,2 ]
Mendell, Jerry R. [1 ,2 ]
机构
[1] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH 43205 USA
[2] Ohio State Univ, Dept Pediat & Neurol, Columbus, OH 43210 USA
关键词
NATURAL-HISTORY; DOUBLE-BLIND; MUSCLE FUNCTION; MOUSE MODEL; DMD; PREDNISONE; TRIAL; GENE; EXPRESSION; SKELETAL;
D O I
10.1016/j.spen.2021.100877
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is marked by pathogenic variants in the DMD gene, leading to reduced or absent dystrophin translation, muscle fiber destruction, loss of ambulation, cardiomyopathy, respiratory failure, and eventually death. Disease progression is slowed with use of prednisone or other corticosteroid agents. Gene replacement therapy, which is one of the focus points of this review, has emerged as the most promising potential treatment for DMD, though alternative RNA-based strategies have been employed for patients with specific pathogenic variants. While challenges remain, many of these novel therapeutic approaches hold promise for treating this devastating disease. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy
    Dominic J. Wells
    Journal of Muscle Research & Cell Motility, 2006, 27 : 387 - 398
  • [32] Common therapeutic advances for Duchenne muscular dystrophy (DMD)
    Salmaninejad, Arash
    Abarghan, Yousef Jafari
    Qomi, Saeed Bozorg
    Bayat, Hadi
    Yousefi, Meysam
    Azhdari, Sara
    Talebi, Samaneh
    Mojarrad, Majid
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2021, 131 (04) : 370 - 389
  • [33] THERAPEUTIC TRIAL OF ISAXONINE IN DUCHENNE MUSCULAR-DYSTROPHY
    DUBOWITZ, V
    HECKMATT, JZ
    HYDE, SA
    GABAIN, A
    MUSCLE & NERVE, 1986, 9 (05) : 270 - 270
  • [34] Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy
    Ogura, Yuji
    Tajrishi, Marjan M.
    Sato, Shuichi
    Hindi, Sajedah M.
    Kumar, Ashok
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2014, 2
  • [35] Therapeutic potential of adiponectin and adipoRon in Duchenne muscular dystrophy
    Lecompte, S.
    Abou-Samra, M.
    Boursereau, R.
    Noel, L.
    Brichard, S.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S261 - S261
  • [36] Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy
    Wells, Dominic J.
    JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 2006, 27 (5-7) : 387 - 398
  • [37] Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
    D'Ambrosio, Eleonora S.
    Mendell, Jerry R.
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1669 - 1681
  • [38] Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy
    Cohen, Justin
    DeSimone, Alec
    Lek, Monkol
    Lek, Angela
    TRENDS IN MOLECULAR MEDICINE, 2021, 27 (02) : 123 - 137
  • [39] Outcome measures in Duchenne muscular dystrophy: Are we ready for the new therapeutic era?
    Merkies, Ingemar S. J.
    Faber, Catharina G.
    NEUROMUSCULAR DISORDERS, 2009, 19 (06) : 447 - 447
  • [40] A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation
    Sun, Zeren
    Xu, Dengqiu
    Zhao, Lei
    Li, Xihua
    Li, Sijia
    Huang, Xiaofei
    Li, Chunjie
    Sun, Lixin
    Liu, Bing
    Jiang, Zhenzhou
    Zhang, Luyong
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (06) : 1237 - 1250